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Abstract
Background: Chronic idiopathic lymphoplasmacytic rhinitis (CILPR) is a common
inflammatory disorder of unknown etiology affecting the nasal cavity of dogs. The
diagnosis is made by exclusion of other causes of nasal disease and specific therapeu-
tic protocols are lacking. In human medicine, a relationship between CILPR and gas-
trointestinal clinical signs has been postulated, and remission of respiratory signs
after clinical trials with medications for gastrointestinal disorders has been observed.
Objectives: To describe history, clinical presentation, endoscopic and histopathologic
concurrent respiratory and digestive tract abnormalities, and to evaluate improve-
ment of respiratory signs after treatment for gastrointestinal signs.
Animals: Twenty-five dogs with CILPR.
Methods: Prospective study. For inclusion, following information had to be available:
respiratory and digestive clinical signs, airway and digestive tract endoscopic abnor-
malities, histologic evaluation of respiratory and gastrointestinal tract biopsy speci-
mens, and clinical response to different treatment strategies.
Results: Twenty-two dogs had endoscopic gastrointestinal lesions, whereas 13 dogs
had concurrent gastrointestinal signs. Most esophageal and duodenal endoscopic
abnormalities were classified as moderate or severe. Respiratory and gastrointestinal
tract histologic evaluation identified mostly chronic inflammation. Remission or mar-
ked improvement of respiratory signs was observed in the majority of dogs treated
only for gastrointestinal signs up to 12 months after endoscopy. No significant asso-
ciations between treatments and follow-up information were found.
Conclusion and Clinical Importance: Nasal and upper digestive tract abnormalities
coexist in some dogs with CILPR. Lack of standardized therapeutic protocols suggests
caution when interpreting improvement in nasal clinical signs. Additional studies are
needed to explore the possibility of a cause-effect relationship between the 2 processes.
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1 | INTRODUCTION
Chronic idiopathic lymphoplasmacytic rhinitis (CILPR) is a common
inflammatory disorder of the nasal cavity in dogs.1-4 It is characterized by
nonpathognomonic clinical signs, including unilateral or bilateral nasal dis-
charge, epistaxis, reverse sneezing, stridor, and inspiratory dyspnea.1,2,4,5
Diagnosis usually is based on histopathologic identification of infiltrating
plasma cells and lymphocytes in the nasal mucosa and exclusion of other
underlying diseases.2,6 The etiology of CILPR remains unknown. Several
hypotheses have been proposed, such as innate immunity and hypersen-
sitivity, odontogenic causes, and bacterial or fungal infection.1-3,7 More-
over, CILPR is not only a diagnostic but also a therapeutic challenge for
clinicians. No specific protocols are available for treating the disease, and
only a single clinical trial has been reported.8 In human medicine, CILPR
remains a major problem of public health worldwide.9 Many studies have
postulated a relationship between CILPR and gastrointestinal clinical
signs such as those related to gastroesophageal reflux disease
(GERD).10-12 However, it is difficult to establish a direct relationship
between CILPR and GERD, because both entities are highly prevalent,
which makes it likely for them to coexist independently.13 Gastroesopha-
geal reflux disease can affect the nasal cavity directly by introduction of
acid, pepsin, and gastric contents into the nasal cavity, or indirectly by
stimulating the autonomic nervous system.14,15 As frequently reported,
the respiratory clinical signs can be the only clinical manifestation of
GERD in humans, confusing the clinician about the correct diagnosis.16-20
However in these cases, remission of respiratory clinical signs after a clin-
ical trial with PO proton-pump inhibitors, prokinetics, diet, or some com-
bination of these may confirm the diagnosis.16,18-21 It is thought that
GERD also occurs in dogs because the clinical findings and response to
treatment are similar to those reported in humans.22-28 It has been
observed in brachycephalic and nonbrachycephalic dogs, and may be
more common than previously suspected.29,30 Although the approach to
diagnosis of GERD has improved recently,31 specific diagnostic criteria
are still lacking and a tentative diagnosis is made if clinical signs and
endoscopic findings suggestive of esophageal involvement are present,
other esophageal and extra-esophageal diseases have been ruled out,
and response to treatment is adequate.22,23 Most dogs with clinical signs
related to GERD, however, do not have identifiable endoscopic mucosal
lesions or other evidence of gastroesophageal reflux.32
To our knowledge, no information exists about a possible associa-
tion between CILPR and gastrointestinal clinical signs in dogs. Thus, our
prospective study was designed to: (1) describe the history, clinical pre-
sentation, concurrent endoscopic and histopathologic respiratory, and
digestive abnormalities in a population of dogs with CILPR, and (2) evalu-
ate improvement of respiratory signs in dogs that received treatment for
gastrointestinal signs.
2 | MATERIALS AND METHODS
Client-owned dogs with chronic upper respiratory clinical signs lasting
for at least 3 weeks and a presumptive diagnosis of CILPR that pres-
ented to different referral clinics of northwest Italy over a 2-year
period (2015-2017) were considered for enrollment. At admission,
each dog's case history was obtained from the owner, as well as infor-
mation about previous diagnostic evaluation, and response to specific
treatments. A clinical examination was performed, body weight was
recorded, and 9-point body condition score (BCS) was assigned. In
addition, a case-based diagnostic evaluation, including survey skull
radiographs, thoracic radiographs, and bronchoalveolar lavage, was
carried out to complete the previous diagnostic evaluation and rule
out specific upper and lower respiratory diseases as potential causes
of the upper respiratory clinical signs.2,4 Upon owner consent to diag-
nostic and therapeutic procedures, dogs underwent endoscopic evalu-
ation of the airways (nares, rhinopharynx, trachea, and bronchi) and
upper digestive tract (oropharynx, esophagus, stomach, and duode-
num). All endoscopic procedures were performed in standardized
fashion by one of the authors (E. B.).33-35 Rigid (2.7 mm × 18 cm, 30;
mod. 64029, Karl Storz Endoscopia Italia S.r.l., Verona, Italy) and flexi-
ble video endoscopes (6.0 mm × 103 cm; EG-1840, Pentax Italia S.r.l.,
Milano, Italy; 7.8 mm × 140 cm, mod. PV-SG 28-140, Karl Storz Endo-
scopia Italia S.r.l.; 5.0 mm × 55 cm fiberscope; Olympus BF-P40,
Olympus Medical Systems Europe GmbH, Hamburg, Germany) were
used. Images and video clips were acquired using video recording
devices (Pinnacle Studio 21.5; Corel Corporation, Ottawa, Canada;
Tele Pack Vet X Led, Karl Storz Endoscopia Italia S.r.l.). Mucosal
biopsy specimens from the nasal cavity, stomach, and duodenum were
submitted for histologic evaluation by a single pathologist. A presump-
tive diagnosis of CILPR was made based on histopathologic identifica-
tion of infiltrating plasma cells and lymphocytes in the nasal mucosa
and exclusion of other underlying diseases, as described elsewhere.2,4
The severity of nasal endoscopic abnormalities was subjectively classi-
fied as normal (no evidence of abnormalities), mild (mild focal or dif-
fuse hyperemia or edema, mild accumulation of mucoid secretions,
mild mucosal hyperplasia), or moderate to severe (marked diffuse
hyperemia or edema, abundant accumulation of mucoid or muco-
purulent secretions, marked mucosal or polypoid hyperplasia, mucosal
erosions, presence of necrotic turbinates). The severity of gastrointes-
tinal endoscopic abnormalities was subjectively classified as normal
(no evidence of abnormalities), mild, or moderate to severe. The fol-
lowing mucosal variables were evaluated: dyschromia, hyperemia,
edema, follicular changes, hypertrophy or granularity, and erosion or
ulcers. Video documentation for each dog was independently
reviewed by 2 authors (E. B., P. G.) in a blinded, separate fashion to
subjectively classify the severity of the endoscopic lesions. A discus-
sion to reach consensus was done only in cases of divergent opinion.
Histologic examination of nasal mucosal biopsy specimens was
assessed based on a previously proposed histologic nasal inflamma-
tion scoring system.36 The lesions were graded as absent, mild, mod-
erate, or severe. Histologic examination of gastroduodenal mucosal
biopsy specimens was performed according to a quantitative simpli-
fied scoring system.37 The lesions were graded as absent, mild, moder-
ate, or severe.
Based on the severity of clinical signs, endoscopic abnormalities,
and histopathologic results in each dog, selected medications were
allowed. For respiratory clinical signs only, systemic (prednisolone) or
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topical (fluticasone, betamethasone) glucocorticoids, antibiotics
(enrofloxacin, amoxicillin-clavulanic acid), or mucolytics (acetylcysteine,
ambroxole) could have been prescribed to dogs, whereas for digestive clin-
ical signs only H2 antagonists (ranitidine), protonpump inhibitors (omepra-
zole, pantoprazole, esomeprazole) or hydrolyzed protein diets could have
been prescribed. In cases of digestive clinical signs or endoscopic abnor-
malities, gastrointestinalmedications as the only therapeutic strategywere
recommended.
Efficacy of the treatments was assessed by re-examination of the
dogs by the attending clinician at 15 days, and 2, 3, 6, and 12 months
after endoscopy. Information on remission, marked improvement, per-
sistence, worsening, or relapse of respiratory clinical signs during or
after cessation of treatment was recorded. Marked improvement was
defined as sporadic respiratory signs less than once monthly. Worsen-
ing was defined as the presence of new respiratory signs, any increase
in severity or frequency of previous respiratory signs or both.
2.1 | Statistical analysis
Statistical analyses were performed using the free software environ-
ment for statistical computing (R, version 3.6.1, available at: https://
www.r-project.org; RStudio, version 1.2.1335; available at: https://
rstudio.com). Continuous variables were expressed as median (mini-
mum and maximum) or percentage. The following variables were
dichotomized: sex (male versus female), breed (breed versus mixed
breed), respiratory clinical signs (sneezing versus not sneezing), gastro-
intestinal clinical signs (vomiting versus not vomiting), treatment strat-
egies (treatments only for gastrointestinal signs versus treatments for
respiratory signs or combination of treatments for both respiratory
and gastrointestinal signs), and follow-up information. Fisher's exact
test was used to detect associations between sex or breed and respi-
ratory or gastrointestinal signs and severity of endoscopic or histo-
logic abnormalities. The Wilcoxon-Mann-Whitney test was used to
detect associations between age or weight and respiratory or gastro-
intestinal signs. The Chi-squared test was used to detect associations
between BCS and respiratory or gastrointestinal signs and severity of
endoscopic or histologic abnormalities. The Kruskal-Wallis test was
used to detect associations between age or weight and severity of
endoscopic or histologic abnormalities. Associations between severity
of nasal and gastrointestinal endoscopic abnormalities, severity of
nasal and gastrointestinal histologic abnormalities, severity of nasal
endoscopic and histologic abnormalities, and severity of gastrointesti-
nal endoscopic and histologic abnormalities, treatment strategies, and
follow-up information were evaluated using Fisher's exact test. Values
of P < .05 were considered significant.
3 | RESULTS
Twenty-five dogs with CILPR were included in the study, subdivided
as follow: 10 mixed breed dogs (40%), 4 Jack Russell terriers (16%),
3 Labrador retrievers (12%), 2 Golden retrievers (8%), 2 Dachshunds
(8%), 1 Pinscher (4%), 1 Akita Inu (4%), 1 Poodle (4%), and 1 English
Setter (4%). Thirteen (52%) dogs were male (2 neutered) and 12 (48%)
were female (9 spayed). The median age was 7.2 years (range, 1-12).
The median body weight was 16 kg (range, 2.5-42). The median BCS
was 5.6 (range, 4-8). Table 1 shows all presenting respiratory clinical
signs. Sneezing (20 dogs, 80%) was most common, followed by nasal
discharge (16 dogs, 64%), which was serous (6 dogs, 37.5%), mucoid
(6 dogs, 37.5%), or purulent (4 dogs, 25%). Thirteen dogs (52%) had
gastrointestinal clinical signs in addition to respiratory clinical signs
(Table 1). Gastrointestinal clinical signs were intermittent (up to once
weekly) or sporadic (less than once monthly) in 12 dogs (48%), and in
the remaining dog (4%) occurred on a daily basis.
A significant association between age and respiratory clinical
signs was found (median age 9 years, P < .04). Distribution of clinical
signs among sex, breed, and BCS is shown in Table 2.
No abnormalities were found on abdominal ultrasonography per-
formed in dogs with vomiting and anorexia before referral. Previous
symptomatic treatments for respiratory clinical signs had failed in
22 (84%) dogs. The remaining 4 (16%) dogs had not received any
treatment. Seven of these 21 dogs (33.3%) were treated using a single
antibiotic (amoxicillin-clavulanic acid 12.5 mg/kg PO q12h, doxycy-
cline 5 mg/kg PO q12h or marbofloxacin 2 mg/kg PO q24h for
1-2 weeks), 6 dogs (28.6%) with a combination of antibiotic and sys-
temic glucocorticoids (prednisone or prednisolone at an initial dosage
of 1 mg/kg PO q24h for 7-10 days, then tapered to 0.5 mg/kg PO
q48h for 2-3 weeks), 5 dogs (23.8%) with nonsteroidal anti-
inflammatory drugs (meloxicam 0.1 mg/kg or carprofen 1 mg/kg PO
q24h for 2-3 weeks), 2 dogs (9.5%) with mucolytics (acetylcysteine
50 mg of a 2% solution nebulized over 30 minutes q12h for 1 week),
TABLE 1 Presenting respiratory and gastrointestinal clinical signs
in 25 dogs with chronic idiopathic rhinitis
Presenting clinical signs
Number of
dogs (%)
Sneezing 7 (28%)
Sneezing, nasal discharge 10 (40%)
Sneezing, nasal discharge, stertor 2 (8%)
Sneezing, nasal discharge, epistaxis 1 (4%)
Nasal discharge, reverse sneezing 1 (4%)
Nasal discharge, stertor 2 (8%)
Reverse sneezing and stertor 1 (4%)
Reverse sneezing 1 (4%)
Sporadic, nonproductive cough 8 (32%)
Vomiting 7 (53.8%)
Vomiting, anorexia, repeated swallowing, and
eructation
2 (15.4%)
Vomiting, retching, and borborygmus 1 (7.7%)
Vomiting, hypersalivation, and episodic praying
position
1 (7.7%)
Anorexia, repeated swallowing, and eructation 1 (7.7%)
Retching and borborygmus 1 (7.7%)
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and 1 dog (4.8%) with topical glucocorticoids (fluticasone 2 sprays
q24h for 2 weeks). Gastrointestinal clinical signs did not worsen while
dogs were receiving glucocorticoids or nonsteroidal anti-inflammatory
drugs. Except for deworming, none of the 13 dogs with gastrointesti-
nal clinical signs had received previous symptomatic treatment.
Twenty-one dogs (84%) were fed a commercial maintenance diet, and
4 dogs (16%) a home-prepared diets with different protein and carbo-
hydrate sources.
Other than slight opacification, pathological changes were not
observed in radiographs of the nasal cavities. Thoracic radiographs
were normal in all dogs. Nasopharyngeal endoscopic abnormalities are
TABLE 2 Distribution of respiratory and digestive clinical signs and severity of endoscopic and histologic abnormalities among sex, breed,
and BCS in 25 dogs with chronic idiopathic rhinitis
RS DS ENA EGA EDA HNA HGA HDA
Sneezing/not sneezing Vomiting/not vomiting M/S N/MD/M/S N/MD/M/S M/MD/S N/MD/M MD/M/S
Sex P = .32 P = 1 P = .43 P = .16 P = .17 P = .31 P = .18 P = 1
F 11/1 5/1 6/6 0/8/3/1 0/3/4/0 3/8/1 2/9/1 6/2/1
ML 9/4 6/1 9/4 4/6/3/0 3/1/3/2 7/5/1 0/9/4 7/4/1
Breed P = .61 P = .19 P = .44 P = .51 P = .32 P = .71 P = .54 P = 1
MB 9/1 4/2 5/5 3/5/2/0 2/3/2/0 4/6/0 1/6/3 5/2/1
P 11/4 7/0 10/5 1/9/4/1 1/1/5/2 6/7/2 1/12/2 8/4/1
BCS P = .59 P = .19 P = .15 P = .58 P = .35 P = .32 P = .76 P = .85
4 3/0 1/0 1/2 0/2/1/0 0/1/2/0 0/3/0 0/2/1 1/1/1
5 9/3 8/1 9/3 4/4/3/1 3/1/3/2 7/5/0 1/8/3 7/4/1
6 4/1 1/0 4/1 0/5/0/0 0/2/1/0 1/3/1 0/4/1 3/1/0
7 3/0 1/0 1/2 0/2/1/0 — 1/1/1 1/2/0 1/0/0
8 1/1 0/1 0/2 0/1/1/0 — 1/1/0 0/2/0 1/0/0
Abbreviations: BCS, body condition score; DS, digestive signs; EDA, severity of endoscopic duodenal abnormalities; EGA, severity of endoscopic gastric
abnormalities; ENA, severity of endoscopic nasal abnormalities; F, female; HDA, severity of histologic duodenal abnormalities; HGA, severity of histologic
gastric abnormalities; HNA, severity of histologic nasal abnormalities; M, moderate; MB, mixed breed; MD, mild; ML, male; N, normal; P, purebred; RS,
respiratory signs; S, severe.
TABLE 3 Nasopharyngeal and gastrointestinal endoscopic
abnormalities in dogs with chronic idiopathic rhinitis
Endoscopic site Endoscopic findings n/t
Nasal cavity Bilateral diffuse hyperemia 25/25 (100%)
Nasal cavity Bilateral diffuse edema 18/25 (72%)
Nasal cavity Bilateral accumulation of
mucoid secretions
12/25 (48%)
Nasal cavity Bilateral accumulation of
mucopurulent secretions
2/25 (8%)
Pharynx Diffuse hyperemia and
edema
2/25 (8%)
Esophagus Hyperemia and erosions in
the caudal thoracic
esophagus
1/22 (4.5%)
Stomach Hyperemia and edema 9/22 (40.9%)
Duodenum Diffuse hyperemia and
edema
1/22 (4.5%)
Stomach (1)
+ Duodenum (2)
Diffuse hyperemia and
edema (1, 2), increased
granularity (2), erosion (2)
12/22 (54.5%)
Note: n/t = number of dogs (%) with a particular endoscopic finding/total
number of dogs with nasal or gastrointestinal endoscopic lesions.
TABLE 4 Nasal and gastrointestinal histopathology findings in 25
dogs with chronic idiopathic rhinitis
Anatomical
district Histopathology findings n/t
Nasal cavity Bilateral lymphocytic-plasmacytic
inflammation
24/25 (96%)
Neutrophilic superimposition 9/25 (36%)
Eosinophilic infiltration 2/25 (8%)
Hyperplasia 25/25 (100%)
Squamous metaplasia 3/25 (12%)
Erosive neutrophilic infiltration 1/25 (4%)
Stomach Lymphocytic-plasmacytic
inflammation
21/25 (84%)
Neutrophilic superimposition 3/25 (12%)
Eosinophilic infiltration 1/25 (4%)
Fibrosis 4/25 (16%)
Duodenum Lymphocytic-plasmacytic
inflammation
19/21 (90.5%)
Neutrophilic superimposition 5/21 (23.8%)
Eosinophilic infiltration 2/21 (9.5%)
Villus stunting 11/21 (52.4%)
Crypt dilatation 7/21 (33.3%)
Lacteal dilatation 1/21 (4.8%)
Note: n/t = number of dogs (%) with the histopathology finding/total num-
ber of dogs in which nasal or gastrointestinal histopathology was consid-
ered adequate.
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shown in Table 3 and were classified as moderate to severe in all
dogs. Laryngeal function was normal in all dogs. No tracheal or bron-
chial endoscopic abnormalities were observed. Bronchoalveolar
lavage cytology was performed in dogs with cough and was normal.
Overall, 22 dogs (88%) had endoscopic gastrointestinal lesions.
Of these, 10 dogs (45.5%) had gastrointestinal clinical signs. The
remaining 3 dogs (23.1%) with gastrointestinal clinical signs had no
endoscopic digestive abnormalities, whereas 12 dogs (54.5%) with-
out gastrointestinal clinical signs had endoscopic digestive abnor-
malities. Gastrointestinal endoscopic abnormalities are shown in
Table 3. All esophageal abnormalities were classified as moderate
to severe; gastric abnormalities were mild in 14 dogs (66.7%) and
moderate to severe in 7 dogs (33.3%); intestinal abnormalities
were mild in 4 dogs (30.8%) and moderate to severe in
9 dogs (69.2%).
With regard to nasal biopsy specimens, tissue quality was
classified as adequate in all cases. The overall severity of lesions
was graded as mild, moderate, or severe in 10 (40%), 13 (52%),
and 2 (8%) dogs, respectively. With regard to gastrointestinal
biopsy specimens, tissue quality was classified as inadequate for
duodenal specimens from 4 dogs. The overall severity of gastric
lesions was graded as mild or moderate in 18 (72%) and 5 (20%)
dogs, respectively. No lesions were found in 2 (8%) dogs. The
overall severity of duodenal lesions was graded as mild, moder-
ate, or severe in 13 (61.9%), 6 (28.6%), and 2 (9.5%) dogs, respec-
tively. Nasal and gastrointestinal histopathology results are shown
in Table 4. No significant associations were found between sig-
nalment and severity of endoscopic or histologic abnormalities or
between severity of endoscopic and histologic abnormalities. Dis-
tribution of severity of endoscopic and histologic abnormalities
according to sex, breed and BCS, and scores is shown in Tables 2
and 5, respectively.
In 23 dogs (92%), different treatments were prescribed after
endoscopic examination. For the remaining 2 dogs, this informa-
tion was not recorded. Three treatment groups were identified.
The first group included 5 dogs (21.7%) treated only with medica-
tions for respiratory clinical signs. All 5 dogs received glucocorti-
coids and antibiotics. In addition, 2 dogs received mucolytics. The
second group included 7 dogs (30.4%) treated only for gastrointes-
tinal clinical signs. Of these dogs, 4 (17.4%) received protonpump
inhibitors or H2 antagonists and 3 (13%) received hydrolyzed pro-
tein diets. The third group included 11 dogs (47.8%) treated for
both respiratory and gastrointestinal clinical signs. All of these
dogs received glucocorticoids, antibiotics, H2 antagonists, and
hydrolyzed protein diets. All treatments lasted from a few days to
1 month and were interrupted within 1 month of endoscopy.
Follow-up information on respiratory clinical signs is shown in
Table 6. Nine dogs (53.8%) showed remission of gastrointestinal
signs within 2 months after endoscopy. For the remaining 4 dogs,
this information was not recorded. No significant associations
between treatment strategies and follow-up information on respi-
ratory clinical signs were found.
TABLE 5 Distribution of severity of endoscopic and histologic abnormalities among scores
EGA EDA HNA HGA HDA
N/MD/M/S N/MD/M/S MD/M/S N/MD/M MD/M/S
ENA P = .76 P = .26 P = .95 — —
M 2/9/3/1 1/3/6/2 6/8/1
S 2/5/3/0 2/1/1/0 4/5/1
HNA — — — P = .12 P = .47
MD 1/8/1 6/3/0
M 0/9/4 5/3/2
S 1/1/0 2/0/0
EGA — — — P = .63 —
N 0/2/2
MD 2/10/2
M 0/5/1
S 0/1/0
EDA — — — — P = .85
N 1/1/1
MD 2/2/0
M 4/2/1
S 1/1/0
Abbreviations: EDA, severity of endoscopic duodenal abnormalities; EGA, severity of endoscopic gastric abnormalities; ENA, severity of endoscopic nasal
abnormalities; HDA, severity of histologic duodenal abnormalities; HGA, severity of histologic gastric abnormalities; HNA, severity of histologic nasal
abnormalities; M, moderate; MD, mild; N, normal; S, severe.
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4 | DISCUSSION
We aimed to explore the concurrent presence of upper respiratory
and digestive endoscopic and histopathologic abnormalities in a popu-
lation of dogs with a presumptive diagnosis of CILPR. In addition, the
response to different treatments and eventual improvement in respi-
ratory clinical signs during treatment for gastrointestinal clinical signs
is reported.
Consistent with previous observations, middle-aged to old dogs
of any sex, breed, or size were affected by idiopathic rhinitis.2,4 Sneez-
ing associated with different types of chronic discharge was the most
commonly recorded respiratory sign. The mucopurulent nature of the
nasal discharge found in the majority of dogs reported here likely
reflects the chronicity of inflammation. Indeed, bacterial culture of
nasal samples often yields minimal to no growth and response to anti-
biotic treatment is poor,2,4,38 as observed in our study. Coughing nor-
mally is associated with lower respiratory tract disease,39,40 but it also
has been reported in dogs with idiopathic rhinitis.38 In affected
humans, rhinitis is considered a frequent extra-esophageal sign of
GERD.19,41-43 In our study, 8 dogs had a history of sporadic, nonpro-
ductive cough. Pneumonia, bronchitis, or tracheal diseases were ruled
out, and therefore coughing may have been a result of vomiting
or GERD. However, cough secondary to pharyngitis caused by
swallowing of irritant nasal secretions remains a possibility.38 The
most consistent findings on rhinoscopy were hyperemia, edema, and
accumulation of mucoid material within the nasal passage, as previ-
ously reported.2,4,44 Chronic idiopathic lymphoplasmacytic rhinitis is
difficult to differentiate from fungal rhinitis by radiography or endos-
copy because both can cause turbinate destruction.2 However, turbi-
nate destruction tends to be less severe in dogs with CILPR compared
with dogs with fungal rhinitis.45 In addition to turbinate destruction, mass-
like lesions mimicking nasal neoplasia can be visualized rhinoscopically.2,46
Computed tomography is more sensitive and specific than is radiography
or endoscopy in differentiating CILPR, nasal neoplasia, and fungal rhinitis.2
Turbinate destruction or mass-like lesions were not detected in our study,
however.
In addition to respiratory clinical signs, half of the dogs reported
here had gastrointestinal clinical signs, most of which were compatible
with GERD.30 However, in contrast to humans in whom clinical signs
such as “heartburn” and acid eructation are considered indicative of
GERD, clinical signs in dogs are less specific. Indeed, previous studies
showed that only 20% to 25% of dogs with clinical signs suggesting
gastroesophageal reflux had GERD.31,32 This observation means that
a reliable diagnosis of GERD in dogs should be based on pH measure-
ment or histologic evaluation of esophageal samples.30,47 Most dogs
in our study (88%) had gastrointestinal endoscopic lesions. Interest-
ingly, these lesions also were found in dogs with only upper respira-
tory clinical signs. Intermittent or sporadic gastrointestinal clinical
signs unnoticed by the owners or a subclinical gastrointestinal process
are possible explanations. Another interesting finding of our study is
the coexistence of both nasal and gastrointestinal lymphoplasmacytic
inflammation in approximately 80% of dogs with and without diges-
tive clinical signs. Different hypotheses could be formulated. First,
because the clinical utility of gastrointestinal histopathology has come
under scrutiny because of a lack of correlation between clinical signs
and response to treatment, gastrointestinal histopathology may not
necessarily reflect clinical disease.48,49 Second, because this type of
inflammatory infiltrate is nonspecific, 2 distinct underlying pathologic
processes of both the respiratory and digestive systems could be pre-
sent.2,4,37,48,50 Indeed, because dogs did not undergo a complete and
TABLE 6 Follow-up information on respiratory clinical signs of dogs with chronic idiopathic rhinitis
Treatment groups
15 days 2 months 3 months 6 months 12 months
n = 22 n = 22 n = 22 n = 21 n = 15
Medications for respiratory clinical signs only R (-) R 2 R (2) R (2) R (3)
MI (5) MI (2) MI (2) MI (1) MI (-)
P (-) P (1) P (-) P (-) P (-)
RP (-) RP (-) RP (1) RP (-) RP (-)
W (-) W (-) W (-) W (2) W (2)
Medications for gastrointestinal clinical signs only R (3) R (4) R (4) R (3) R (2)
MI (3) MI (3) MI (3) MI (2) MI (2)
P (1) P (-) P (-) P (-) P (-)
RP (-) RP (-) RP (-) RP (1) RP (2)
W (-) W (-) W (-) W (-) W (-)
Medications for respiratory and gastrointestinal clinical signs R (1) R (2) R (2) R (3) R (1)
MI (4) MI (2) MI (2) MI (3) MI (-)
P (5) P (5) P (4) P (2) P (2)
RP (-) RP (1) RP (1) RP (1) RP (-)
W (-) W (-) W (1) W (1) W (1)
Abbreviations: (n), number of dogs with a specific follow-up information; MI, marked improvement; n, number of dogs in which follow-up information is
available; P, persistence; R, remission; RP, relapse; W, worsening.
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standardized evaluation for their gastrointestinal signs, coexistence of
CILPR and chronic enteropathy is a possibility. Third, a primary diges-
tive problem with secondary chronic exposure of the respiratory
mucosa to acid reflux could not be ruled out.16,19,42,51,52 However, if
this were the case, a marked response to protonpump inhibitor treat-
ment should have been observed. Moreover, because treatments
were not standardized and not all dogs received protonpump inhibi-
tors, firm conclusions about the improvement in observed nasal clini-
cal signs cannot be drawn.
Current literature suggests that partial to almost complete response
to glucocorticoids can be observed in some dogs with CILPR.2,4,6 Instead,
anti-inflammatory drugs and antibiotics have shown variable therapeutic
effects.2,4 Other treatment strategies include the combination of a gluco-
corticoid and a nonsteroidal anti-inflammatory drug;8 a combination of
glucocorticoids, cyclosporine and desensitization,4 and use of antifungal
medications and inhaled steroids.2,53 In our study, all dogs that received
previous symptomatic treatment for respiratory clinical signs failed to
show resolution or sustained improvement. Whether the dose or length
of prescribed drugs was inappropriate or a mechanism other than
immune-mediated inflammation was responsible was not investigated.
Interestingly, most of the dogs that received only a gastrointestinal thera-
peutic approach showed complete remission or sustained improvement
of respiratory clinical signs up to 12 months after endoscopy. Moreover,
according to information from the client, gastrointestinal signs resolved
in the majority of the dogs. Based on these findings and observations
from human medicine, the hypothesis that acid reflux could be a contrib-
utory cause of upper respiratory clinical signs, although not demon-
strated, cannot be ruled out.19,20,23,30,54 However, the same positive
trend was observed in the remaining 2 groups, and the specific contribu-
tion of glucocorticoids, H2 antagonists or diets is not known, as well as a
possible self-limiting nature of the gastrointestinal clinical signs.
Our study had some limitations, primarily related to relatively
small sample size and lack of a standardized gastrointestinal diag-
nostic evaluation and therapeutic approach. Indeed, without this
information, the clinical utility of some data presented here is
unknown and cannot be adequately interpreted. Particularly, a link
between improvement in respiratory clinical signs and the gastroin-
testinal therapeutic approach may not be present. Indeed, in the
absence of a control population of dogs with other chronic
non-CILPR disease, it is not possible to state that the high preva-
lence of endoscopic gastrointestinal abnormalities and clinical signs
observed here is not at least partially associated with the selection
of chronically sick dogs.
In conclusion, to our knowledge, no information exists about the
concurrent endoscopic evaluation of both the upper airways and
digestive system in dogs with CILPR. Our results suggest that in some
dogs with nasal clinical signs, in which no primary disease could be
identified, some gastrointestinal clinical signs, endoscopic lesions, and
histopathologic abnormalities occur concurrently. In light of these
findings, consideration should be given to the possibility of a cause-
effect relationship between the 2 processes. However, additional
studies are needed to explore the impact of gastrointestinal medica-
tions on respiratory clinical signs.
CONFLICT OF INTEREST DECLARATION
Authors declare no conflict of interest.
OFF-LABEL ANTIMICROBIAL DECLARATION
Authors declare no off-label use of antimicrobials.
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE
(IACUC) OR OTHER APPROVAL DECLARATION
Authors declare no IACUC or other approval was needed.
HUMAN ETHICS APPROVAL DECLARATION
Authors declare human ethics approval was not needed for this study.
ORCID
Paola Gianella https://orcid.org/0000-0003-2744-7120
Giulia Cagnotti https://orcid.org/0000-0003-1287-6723
REFERENCES
1. Meler E, Dunn M, Lecuyer M. A retrospective study of canine persis-
tent nasal disease: 80 cases (1998-2003). Can Vet J. 2008;49:71-76.
2. Windsor RC, Johnson LR. Canine chronic inflammatory rhinitis. Clin
Tech Small Anim Pract. 2006;21:76-81.
3. Lobetti RG. A retrospective study of chronic nasal disease in 75 dogs.
J S Afr Vet Assoc. 2009;80:224-228.
4. Lobetti RG. Idiopathic lymphoplasmacytic rhinitis in 33 dogs. J S Afr
Vet Assoc. 2014;85:1151.
5. Plickert HD, Tichy A, Hirt RA. Characteristics of nasal discharge
related to intranasal disease: a retrospective study of 105 cases.
J Small Anim Pract. 2014;55:145-152.
6. Furtado ARR, Caine A, Herrtage M. Diagnostic value of MRI in dogs with
inflammatory nasal disease. J Small Anim Pract. 2014;55:359-363.
7. Stepaniuk KS, Gingerich W. Suspect odontogenic infection etiology
for canine lymphoplasmacytic rhinitis. J Vet Dent. 2015;32:22-29.
8. Kaczmar E, Rychlik A, Szweda M. The evaluation of three treatment
protocols using oral prednisone and oral meloxicam for therapy of
canine idiopathic lymphoplasmacytic rhinitis: a pilot study. Ir Vet J.
2018;71:19. https://doi.org/10.1186/s13620-018-0131-3.
9. Benninger MS, Ferguson BJ, Hadley JA, et al. Adult chronic
rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiol-
ogy. Otolaryngol Head Neck Surg. 2003;129:S1-S32.
10. Phipps CD, Wood WE, Gibson WS, Cochran WJ. Gastroesophageal
reflux contributing to chronic sinus disease in children: a prospective
analysis. Arch Otolaryngol Head Neck Surg. 2000;126:831-836.
11. Sella GCP, Tamashiro E, Anselmo-Lima WT, Valera FCP. Relation
between chronic rhinosinusitis and gastroesophageal reflux in adults:
systematic review. Braz J Otorhinolaryngol. 2017;83:356-363.
12. Leason SR, Barham HP, Oakley G, et al. Association of gastro-
oesophageal reflux and chronic rhinosinusitis: systematic review and
meta-analysis. Rhinology. 2017;55:3-16.
13. Wong IW, Omari TI, Myers JC, et al. Nasopharyngeal pH monitoring
in chronic sinusitis patients using a novel four channel probe. Laryngo-
scope. 2004;114:1582-1585.
14. DelGaudio JM. Direct nasopharyngeal reflux of gastric acid is a con-
tributing factor in refractory chronic rhinosinusitis. Laryngoscope.
2005;115:946-957.
15. Yao A, Wilson JA, Ball SL. Autonomic nervous system dysfunction
and sinonasal symptoms. Allergy Rhinol. 2018;9:215265671876423.
https://doi.org/10.1177/2152656718764233.
16. Ates F, Vaezi MF. Insight into the relationship between gastroesopha-
geal reflux disease and asthma. Gastroenterol Hepatol. 2014;10:
729-735.
GIANELLA ET AL. 7
17. Mikami DJ, Murayama KM. Physiology and pathogenesis of gastro-
esophageal reflux disease. Surg Clin North Am. 2015;95:515-525.
18. Naik RD, Vaezi F. Extra-esophageal gastroesophageal reflux disease
and asthma: understanding this interplay. Expert Rev Gastroenterol
Hepatol. 2015;9:969-978.
19. Poelmans J, Tack J. Extraoesophageal manifestations of gastro-
oesophageal reflux. Gut. 2005;54:1492-1499.
20. Farrokhi F, Vaezi MF. Extra-esophageal manifestations of gastro-
esophageal reflux. Oral Dis. 2007;13:349-359.
21. Houghton LA, Lee AS, Badri H, DeVault KR, Smith JA. Respiratory
disease and the oesophagus: reflux, reflexes and microaspiration. Nat
Rev Gastroenterol Hepatol. 2016;13:445-460.
22. Han E. Diagnosis and management of reflux esophagitis. Clin Tech
Small Anim Pract. 2003;18:231-238.
23. Muenster M, Hoerauf A, Lubke-Becker A, et al. Idiopathic
esophagopathies resembling gastroesophageal reflux disease in dogs.
Tierarztl Prax Ausg K Kleintiere Heimtiere. 2013;41:173-179.
24. Lux CN, Archer TM, Lunsford KV. Gastroesophageal reflux and laryn-
geal dysfunction in a dog. J Am Vet Med Assoc. 2012;240:1100-1103.
25. Poncet CM, Dupre GP, Freiche VG. Prevalence of gastrointestinal
tract lesions in 73 brachycephalic dogs with upper respiratory syn-
drome. J Small Anim Pract. 2005;46:273-279.
26. Wilson G. Ulcerative esophagitis and esophageal stricture. J Am Anim
Hosp Assoc. 1977;13:180-185.
27. Bissett SA, Davis J, Subler K, Degernes LA. Risk factors and outcome of
bougienage for treatment of benign esophageal strictures in dogs and
cats: 28 cases (1995-2004). J Am Vet Med Assoc. 2009;235:844-850.
28. Gibson CJ, Parry NM, Jakowski RM, et al. Adenomatous polyp with
intestinal metaplasia of the esophagus (Barrett esophagus) in a dog.
Vet Pathol. 2010;47:116-119.
29. Shaver SL, Barbur LA, Jimenez DA, et al. Evaluation of gastroesopha-
geal reflux in anesthetized dogs with brachycephalic syndrome. J Am
Anim Hosp Assoc. 2017;53:24-31.
30. Muenster M, Hoerauf A, Vieth M. Gastro-oesophageal reflux disease
in 20 dogs (2012 to 2014). J Small Anim Pract. 2017;58:276-283.
31. Kook PH, Kempf J, Ruetten M, Reusch CE. Wireless ambulatory
esophageal pH monitoring in dogs with clinical signs interpreted as
gastroesophageal reflux. J Vet Intern Med. 2014;28:1716-1723.
32. Munster M, Kook P, Araujo R, et al. Determination of hyperregeneratory
esophagopathy in dogs with clinical signs attributable to esophageal dis-
ease. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2015;43:147-155.
33. Rawlings CA. Diagnostic rigid endoscopy: otoscopy, rhinoscopy and
cystoscopy. Vet Clin North Am Small Anim Pract. 2009;39:849-868.
34. Creevy KE. Airway evaluation and flexible endoscopic procedures in
dogs and cats: laryngoscopy, transtracheal wash, tracheobronchoscopy,
and bronchoalveolar lavage. Vet Clin North Am Small Anim Pract. 2009;
39:869-880.
35. Sum S, Ward CR. Flexible endoscopy in small animals. Vet Clin North
Am Small Anim Pract. 2009;39:881-902.
36. Furtado ARR, Constantino-Casas F. Histopathology inflammation
scoring and classification in 34 dogs with inflammatory nasal disease.
Vet Rec. 2013;173:71.
37. Allenspach KA, Mochel JP, Du Y, et al. Correlating gastrointestinal
histopathologic changes to clinical disease activity in dogs with idio-
pathic inflammatory bowel disease. Vet Pathol. 2018;56:435-443.
38. Windsor RC, Johnson LR, Herrgesell EJ, de Cock HEV. Idiopathic
lymphoplasmacytic rhinitis in dogs: 37 cases (1997-2002). J Am Vet
Med Assoc. 2004;224:1952-1957.
39. Rozanski E. Canine chronic bronchitis. Vet Clin North Am Small Anim
Pract. 2014;44:107-116.
40. Cohn LA. Canine nasal disease. Vet Clin North Am Small Anim Pract.
2014;44:75-89.
41. Harding SM, Hallen JE, Blumin JH, et al. Respiratory manifestations
of gastroesophageal reflux disease. Ann N Y Acad Sci. 2013;1300:
43-52.
42. Herregods TVK, Pauwels A, Jafari J, et al. Determinants of reflux-
induced chronic cough. Gut. 2017;12:2062.
43. Stein MR. Possible mechanisms of influence of esophageal acid on
airway hyperresponsiveness. Am J Med. 2003;115:55-59.
44. Tasker S, Knottenbelt CM, Munro EA, et al. Aetiology and diagnosis
of persistent nasal disease in the dog: a retrospective study of
42 cases. J Small Anim Pract. 1999;40:473-478.
45. Lefebvre J, Kuehn NF, Wortinger A. Computed tomography as an aid
in the diagnosis of chronic nasal disease in dogs. J Small Anim Pract.
2005;46:280-285.
46. Willard MD, Radlinsky MA. Endoscopic examination of the choanae
in dogs and cats: 118 cases (1988-1998). J Am Vet Med Assoc. 1999;
215:1301-1305.
47. Tarvin KM, Twedt DC, Monnet E. Prospective controlled study of
gastroesophageal reflux in dogs with naturally occurring laryngeal
paralysis. Vet Surg. 2016;45:916-921.
48. Garcia-Sancho M, Rodriguez-Franco F, Sainz A, et al. Evaluation of
clinical, macroscopic, and histopathologic response to treatment in
nonhypoproteinemic dogs with lymphocytic-plasmacytic enteritis.
J Vet Intern Med. 2007;21:11-17.
49. Schreiner N, Gaschen F, Grone A, et al. Clinical signs, histology and
CD-3 positive cells before and after treatment of dogs with chronic
enteropathies. J Vet Intern Med. 2008;22:1079-1083.
50. Jacobs G, Collins-Kelly L, Lappin M, Tyler D. Lymphocytic-plasmacytic
enteritis in 24 dogs. J Vet Intern Med. 1990;4:45-53.
51. Lazenby JP, Harding SM. Chronic cough and gastroesophageal reflux.
Curr Gastroenterol Rep. 2000;2:217-223.
52. Tauber S, Gross M, Issing WJ. Association of laryngopharyngeal
symptoms with gastroesophageal reflux disease. Laryngoscope. 2002;
112:879-886.
53. Mercier E, Peeters IR, Billen F, et al. Potential role of Alternaria and
Cladosporium species in canine lymphoplasmacytic rhinitis. J Small
Anim Pract. 2013;54:179-183.
54. Halstead L. Role of gastroesophageal reflux in pediatric upper airway
disorders. Otolaryngol Head Neck Surg. 1999;120:208-214.
How to cite this article: Gianella P, Roncone S, Ala U, et al.
Upper digestive tract abnormalities in dogs with chronic
idiopathic lymphoplasmacytic rhinitis. J Vet Intern Med. 2020;
1–8. https://doi.org/10.1111/jvim.15827
8 GIANELLA ET AL.
